December 12, 2017 09:44 AM EST

Sanofi's R&D day poses some big challenges as skeptics circle in wake of a Dengvaxia fiasco

Bioregnum

The view from John Carroll

Tomorrow the analysts that cover Sanofi $SNY will gather in Paris to hear the pharma giant outline its R&D strategy. And more than a few skeptics from the investor community will be on hand.

After relying on partners like Regeneron $REGN and Alnylam $ALNY to deliver the goods on innovation and significant new progress in drug development, chief scientist Elias Zerhouni believes it’s time to become more self-reliant.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE

TRENDING NOW

Sanofi's R&D day poses some big challenges as skeptics circle in wake of a Dengvaxia fiasco

Bioregnum

The view from John Carroll

This article is for premium subscribers only

J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win

Federal government shutdown watch: FDA and industry prep for likely closure Oct. 1

FDA approves major depressive drug after rejecting it multiple times in past two decades

Stephen Hahn’s liquid biopsy company Harbinger Health raises $140M Series B to launch first cancer tests by 2025

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

5 Patient Engagement & Recruitment Trends, and How to Keep Up with Them

Sanofi's R&D day pos­es some big chal­lenges as skep­tics cir­cle in wake of a Deng­vax­ia fi­as­co

Bioreg­num

The view from John Car­roll

This article is for premium subscribers only

J&J’s chal­lenge to As­traZeneca in lung can­cer takes flight with PhI­II PFS win

Fed­er­al gov­ern­ment shut­down watch: FDA and in­dus­try prep for like­ly clo­sure Oct. 1

FDA ap­proves ma­jor de­pres­sive drug af­ter re­ject­ing it mul­ti­ple times in past two decades

Stephen Hahn’s liq­uid biop­sy com­pa­ny Har­bin­ger Health rais­es $140M Se­ries B to launch first can­cer tests by 2025

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

5 Pa­tient En­gage­ment & Re­cruit­ment Trends, and How to Keep Up with Them

Sanofi's R&D day poses some big challenges as skeptics circle in wake of a Dengvaxia fiasco

Bioregnum

The view from John Carroll

J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win

Federal government shutdown watch: FDA and industry prep for likely closure Oct. 1

FDA approves major depressive drug after rejecting it multiple times in past two decades

Stephen Hahn’s liquid biopsy company Harbinger Health raises $140M Series B to launch first cancer tests by 2025

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

5 Patient Engagement & Recruitment Trends, and How to Keep Up with Them